VAXCYTE, INC. Comprehensive Income
VAXCYTE, INC. (PCVX) reported Comprehensive Income of -$285.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$285.01M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$329.04M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$245.78M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$210.09M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$761.17M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$467.98M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$401.73M.
- VAXCYTE, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$223.60M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$285.01M 10-Q · filed 2026-08-05 | -$614.06M 10-Q · filed 2026-08-05 | -$859.83M derived: sum of 3 quarters · filed 2026-08-05 | -$1.07B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$329.04M 10-Q · filed 2026-05-06 | -$574.82M derived: sum of 2 quarters · filed 2026-05-06 | -$784.91M derived: sum of 3 quarters · filed 2026-05-06 | -$953.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$245.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$455.86M derived: sum of 2 quarters · filed 2026-02-24 | -$624.00M derived: sum of 3 quarters · filed 2026-08-05 | -$761.17M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$210.09M 10-Q · filed 2025-11-04 | -$378.23M derived: sum of 2 quarters · filed 2026-08-05 | -$515.39M 10-Q · filed 2025-11-04 | -$656.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$168.14M 10-Q · filed 2026-08-05 | -$305.31M 10-Q · filed 2026-08-05 | -$446.40M derived: sum of 3 quarters · filed 2026-08-05 | -$551.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$137.17M 10-Q · filed 2026-05-06 | -$278.26M derived: sum of 2 quarters · filed 2026-05-06 | -$383.06M derived: sum of 3 quarters · filed 2026-05-06 | -$512.84M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$141.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$245.89M derived: sum of 2 quarters · filed 2026-02-24 | -$375.67M derived: sum of 3 quarters · filed 2026-02-24 | -$467.98M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$104.80M 10-Q · filed 2025-11-04 | -$234.58M derived: sum of 2 quarters · filed 2025-11-04 | -$326.89M 10-Q · filed 2025-11-04 | -$505.22M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$129.78M 10-Q · filed 2025-08-06 | -$222.09M 10-Q · filed 2025-08-06 | -$400.42M derived: sum of 3 quarters · filed 2026-02-24 | -$492.85M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$92.31M 10-Q · filed 2025-05-07 | -$270.64M derived: sum of 2 quarters · filed 2026-02-24 | -$363.07M derived: sum of 3 quarters · filed 2026-02-24 | -$433.98M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$178.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$270.76M derived: sum of 2 quarters · filed 2026-02-24 | -$341.67M derived: sum of 3 quarters · filed 2026-02-24 | -$401.73M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$92.43M 10-Q · filed 2024-11-05 | -$163.34M derived: sum of 2 quarters · filed 2024-11-05 | -$223.39M 10-Q · filed 2024-11-05 | -$301.15M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$70.91M 10-Q · filed 2024-08-06 | -$130.96M 10-Q · filed 2024-08-06 | -$208.72M derived: sum of 3 quarters · filed 2025-02-25 | -$266.38M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$60.05M 10-Q · filed 2024-05-08 | -$137.81M derived: sum of 2 quarters · filed 2025-02-25 | -$195.48M derived: sum of 3 quarters · filed 2025-02-25 | -$244.08M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$77.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$135.42M derived: sum of 2 quarters · filed 2025-02-25 | -$184.03M derived: sum of 3 quarters · filed 2025-02-25 | -$223.60M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$57.67M 10-Q · filed 2023-11-06 | -$106.27M derived: sum of 2 quarters · filed 2023-11-06 | -$145.85M 10-Q · filed 2023-11-06 | -$174.64M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$48.60M 10-Q · filed 2023-08-08 | -$88.18M 10-Q · filed 2023-08-08 | -$116.97M derived: sum of 3 quarters · filed 2024-02-27 | -$143.59M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$39.58M 10-Q · filed 2023-05-08 | -$68.37M derived: sum of 2 quarters · filed 2024-02-27 | -$94.99M derived: sum of 3 quarters · filed 2024-02-27 | -$118.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$28.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$55.41M derived: sum of 2 quarters · filed 2024-02-27 | -$79.05M derived: sum of 3 quarters · filed 2024-02-27 | -$100.32M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$26.62M 10-Q · filed 2022-11-07 | -$50.26M derived: sum of 2 quarters · filed 2022-11-07 | -$71.53M 10-Q · filed 2022-11-07 | -$92.26M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$23.64M 10-Q · filed 2022-08-08 | -$44.91M 10-Q · filed 2022-08-08 | -$65.64M derived: sum of 3 quarters · filed 2023-02-27 | -$86.66M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$21.27M 10-Q · filed 2022-05-09 | -$42.00M derived: sum of 2 quarters · filed 2023-02-27 | -$63.02M derived: sum of 3 quarters · filed 2023-02-27 | -$83.34M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$41.76M derived: sum of 2 quarters · filed 2023-02-27 | -$62.08M derived: sum of 3 quarters · filed 2023-02-27 | -$89.22M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$21.02M 10-Q · filed 2021-11-10 | -$41.34M derived: sum of 2 quarters · filed 2021-11-10 | -$68.48M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$20.32M 10-Q · filed 2021-08-11 | -$47.46M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$27.14M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$50.27M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |